Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer
- 30 April 2005
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 23 (2), 82-86
- https://doi.org/10.1016/j.urolonc.2004.08.013
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancerBritish Journal of Cancer, 2003
- Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA eraInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Phase II Trial of GM-CSF in Advanced Prostate CancerInvestigational New Drugs, 2001
- LONG-TERM HAZARD OF PROGRESSION AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: CONTINUED RISK OF BIOCHEMICAL FAILURE AFTER 5 YEARSJournal of Urology, 2000
- Granulocyte-macrophage colony-stimulating factor protects dendritic cells from liposome-encapsulated dichloromethylene diphosphonate-induced apoptosis through a Bcl-2-mediated pathwayEuropean Journal of Immunology, 1999
- Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating FactorBlood, 1998
- PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 1997
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996